ArticleCellular and molecular life sciences : CMLS2004
The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma.
Article in Cellular and molecular life sciences : CMLS, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 110 citations in OpenAlex.
- Transcriptional Reprogramming by AP-1-Bound Cis-Regulatory Elements Is Associated with Melanoma Development.International journal of molecular sciences · 2026Article
- Characterization of Ets-1 deficiency-induced depigmentation in a mouse model: insights into vitiligo pathogenesis.Laboratory animal research · 2025Article
- Functional analysis of recurrent CDC20 promoter variants in human melanoma.Communications biology · 2023Article
- SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma.Nature communications · 2023Article
- Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding.JCI insight · 2022Article
- Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface.Nature communications · 2021Article
- Targeting Pan-ETS Factors Inhibits Melanoma Progression.Cancer research · 2021Article
- RGL2 as an age-dependent factor regulates colon cancer progression.Computational and structural biotechnology journal · 2021Article
- Histamine receptors and cancer pharmacology: an update.British journal of pharmacology · 2020Review
- Integrated Analysis of the ETS Family in Melanoma Reveals a Regulatory Role of ETV7 in the Immune Microenvironment.Frontiers in immunology · 2020Article
- ETS1 Suppresses Tumorigenesis of Human Breast Cancer via Trans-Activation of Canonical Tumor Suppressor Genes.Frontiers in oncology · 2020Article
- Genomic sites hypersensitive to ultraviolet radiation.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Neuregulin-1 is a chemoattractant and chemokinetic molecule for trunk neural crest cells.Developmental dynamics : an official publication of the American Association of Anatomists · 2018Article
- Prognostic Value of FBXO39 and ETS-1 but not BMI-1 in Iranian Colorectal Cancer PatientsAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.Neoplasia (New York, N.Y.) · 2018Article
- ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression.Oncotarget · 2017Article
- Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.Nature communications · 2017Article
- TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.Oncotarget · 2016Article
- SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.Oncotarget · 2016Article
- The transcription factors Ets1 and Sox10 interact during murine melanocyte development.Developmental biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ets-1 transcription factor plays a role in tumor vascularization and invasion by regulating expression of matrix-degrading proteases in endothelial cells and fibroblasts in the tumor stroma. During early embryogenesis, Ets-1 is expressed in migrating neural crest cells from which melanocytes arise. In the present study, we analyzed Ets-1 expression in various melanocytic lesions and investigated its functional importance in malignant melanomas. We found that Ets-1 was upregulated both in vivo and in vitro in malignant melanoma, compared to benign melanocytic lesions and to primary melanocytes. Assessment of DNA-binding and transactivation assays documented a strong Ets activity in melanoma cells. Using an antisense strategy, the expression and activity of Ets-1 were reduced in the melanoma cell line Mel Im. This correlated with a diminished expression of several Ets-1 target genes known to be involved in invasion, such as MMP1, MMP3, uPA and integrin beta3. In line with these findings, the invasive potential of the melanoma cells measured in a Boyden Chamber model was reduced up to 60% after Ets-1 blockade. This can be attributed to the role of Ets-1 in transcriptional regulation of factors involved in invasion of melanoma cells. We conclude that over-expression of Ets-1 during melanoma development contributes to the malignant phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.